

IMPORTANT: THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION. IF IN DOUBT, PLEASE SEEK PROFESSIONAL ADVICE.

Each of The Stock Exchange of Hong Kong Limited, Hong Kong Exchanges and Clearing Limited ("HKEX"), Hong Kong Securities Clearing Company Limited and the Securities and Futures Commission (the "SFC") takes no responsibility for the contents of this Announcement, makes no representation as to its accuracy or completeness and expressly disclaims any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this Announcement. The Directors accept full responsibility for the accuracy of the information contained in this Announcement as at the date of publication, and confirms, having made all reasonable enquiries, that to the best of its knowledge and belief, as at the date of publication, opinions expressed in this Announcement have been arrived at after due and careful consideration. SFC authorisation is not a recommendation or an endorsement of a scheme nor does it guarantee the commercial merits of a scheme or its performance. It does not mean the scheme is suitable for all investors nor is it an endorsement of its suitability for any particular investor or class of investors.

Global X ETF Series (the "Trust")

**Global X China Biotech ETF (USD Counter Stock Code: 09820; HKD Counter Stock Code: 02820)
Global X China Cloud Computing ETF (USD Counter Stock Code: 09826; HKD Counter Stock Code: 02826)
(each a "Sub-Fund", and collectively the "Sub-Funds")**

(Each a sub-fund of Global X ETF Series, a Hong Kong umbrella unit trust, authorised under Section 104 of the Securities and Futures Ordinance (Cap. 571) of Hong Kong)¹

Notice to Unitholders – Changes to the Index Methodology of the Sub-Funds

Dear Unitholders,

All capitalised terms in this notice shall have the same meaning as in the Prospectus of the Company and the Sub-Funds (the "**Prospectus**") dated 13 July 2020, unless otherwise stated.

We understand from Solactive AG ("Solactive"), the Index Provider of the Index of each Sub-Fund, that the changes as describe in Section A and Section B below have been made to Index methodology of the Index of each Sub-Fund.

A. Global X China Biotech ETF

Due to the current market conditions, Solactive has refined the Index Methodology to diversify the Index of the Sub-Fund and make it less concentrated in few constituents:

1. Increasing the weight cap from 6% to 9% to limit the excessive overweighting in smaller companies (as described under the sub-section "Weighting" in Appendix 4 of the Prospectus) as follows: *"On each Selection Day, the components of the Underlying Index are weighted according to Free Float Market Capitalization such that the weight of each company in the Underlying Index does not exceed 9%. The excess weight that results from capping is redistributed in proportion to the Free Float Market Capitalization of the other companies constituting the Underlying Index which do not exceed 9%."*
2. Increasing the number of constituents from 20 to 30 (as described under the sub-section "Selection Criteria" in Appendix 4 of the Prospectus) as follows: *"(a) Top 30 by total market capitalization rank are selected for index inclusion. (b) Existing constituents with rank from 20 to 40 are selected for index inclusion until the target constituent count of 30 is reached. (c) If there are less than 30 stocks after step (b), non-constituents are selected with rank from 20 to 40 until the target constituent count of 30 is reached."*

¹ SFC authorisation is not a recommendation or endorsement of a scheme nor does it guarantee the commercial merits of a scheme or its performance. It does not mean the scheme is suitable for all investors nor is it an endorsement of its suitability for any particular investor or class of investors.

3. Introduction of 6 months minimum listing history to avoid companies without sufficient trading history (as described under the sub-section "Index Universe" in Appendix 4 of the Prospectus) as follows: *"The index universe of the Underlying Index ("Index Universe") includes shares of companies headquartered in China or Hong Kong that fulfill the following criteria: 1. Should be listed on one of the following exchanges and should have listing history of at least 6 months: a) Hong Kong: SEHK b) PRC: SSE and SZSE c) United States of America: the New York Stock Exchange and the NASDAQ Stock Market"*

B. Global X China Cloud Computing ETF

Due to the current market conditions, Solactive has refined the Index Methodology to diversify the Index of the Sub-Fund and make it less concentrated in few constituents:

1. Increasing the weight cap from 6% to 9% to limit the excessive overweighting in smaller companies (as described under the sub-section "Weighting" in Appendix 5 of the Prospectus) as follows: *"On each Selection Day, the components of the Underlying Index are weighted according to Free Float Market Capitalization such that the weight of each company in the Underlying Index does not exceed 9%. The excess weight that results from capping is redistributed in proportion to the Free Float Market Capitalization of the other companies constituting the Underlying Index which do not exceed 9%."*
2. Increasing the number of constituents from 20 to 30 (as described under the sub-section "Selection Criteria" in Appendix 5 of the Prospectus) as follows: *"(a) Top 30 by total market capitalization rank are selected for index inclusion. (b) Existing constituents with rank from 20 to 40 are selected for index inclusion until the target constituent count of 30 is reached. (c) If there are less than 30 stocks after step (b), non-constituents are selected with rank from 20 to 40 until the target constituent count of 30 is reached."*
3. Introduction of 6 months minimum listing history to avoid companies without sufficient trading history (as described under the sub-section "Index Universe" in Appendix 5 of the Prospectus) as follows: *"The index universe of the Underlying Index ("Index Universe") includes shares of companies headquartered in China or Hong Kong that fulfill the following criteria: 1. Should be listed on one of the following exchanges and should have listing history of at least 6 months: a) Hong Kong: SEHK b) PRC: SSE and SZSE c) United States of America: the New York Stock Exchange and the NASDAQ Stock Market"*

C. General

For the avoidance of doubt, (i) the investment objective and investment strategy of the Sub-Funds will remain unchanged; (ii) the abovementioned changes will not amount to material changes to the Sub-Funds; (iii) there will be no material change or increase in the overall risk profile of the Sub-Funds; (iv) the abovementioned changes do not materially prejudice the interests of Unitholders; (v) the abovementioned changes will not affect the acceptability of each Index under the SFC's Code on Unit Trusts and Mutual Funds; and (vi) the Sub-Funds' normal operation will not be disrupted.

The revised Prospectus and KFS of the Sub-Funds will be revised on 13 July 2020 to reflect the abovementioned changes, and will be published on the Company's website at www.am.miraeasset.com.hk/globalx² on 13 July 2020 and HKEx's website at www.hkex.com.hk.

Investors who have any enquiries regarding the above may contact the Manager, Mirae Asset Global Investments (Hong Kong) Limited, at Level 15, Three Pacific Place, 1 Queen's Road East, Hong Kong or our enquiry hotline at (852) 2295-1500 during office hours.

The Manager accepts responsibility for the accuracy of the contents of this notice.

Mirae Asset Global Investments (Hong Kong) Limited
As Manager of the Sub-Funds

Date: 13 July 2020

² This website has not been reviewed or approved by the SFC.